Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
复制标题
DOI：
10.1016/j.pathol.2015.12.006
复制
发表时间：
2016-02-01
期刊：
影响因子：
4.5
通讯作者：
Schatton, Tobias
中科院分区：
文献类型：
--
作者：
Lee, Nayoung;Zakka, Labib R.;Schatton, Tobias
随着靶向免疫检查点的新型免疫调节策略的出现，转移性疾病的全身性癌症治疗领域已经进入了一个令人兴奋的时代。这些有希望的努力的核心是肿瘤浸润淋巴细胞（TIL）。随着证实在晚期癌症患者中调节TIL效应子功能的功效的报道不断增加，更好地理解TIL免疫生物学以进一步改善临床结果变得至关重要。除了概述目前转移性黑色素瘤的免疫治疗外，本文还将简要介绍TIL的历史和分类。此外，我们将剖析TIL在肿瘤特异性免疫和黑色素瘤免疫逃逸中的多方面作用。TIL在黑色素瘤预后和癌症免疫治疗中的意义也将被讨论，特别关注其作为患者反应生物标志物的潜在效用。随着新的免疫调节技术和技术创新不断推动癌症免疫治疗领域的发展，个性化医疗的目标似乎已经成为现实。鉴于最近的研究强调了TIL在确定治疗结果中的可能效用，TIL表型和功能的进一步表征有可能帮助将个性化护理转化为当前的医疗实践。
The field of systemic cancer therapy for metastatic disease has entered an exciting era with the advent of novel immunomodulatory strategies targeting immune checkpoints. At the heart of these promising efforts are the tumour-infiltrating lymphocytes (TILs). As the reports demonstrating efficacy of modulating TIL effector function in patients with advanced stage cancer continue to accrue, it has become essential to better understand TIL immunobiology in order to further improve clinical outcome. In addition to providing an overview of the current immunotherapies available for metastatic melanoma, this review will briefly introduce the history and classification of TILs. Moreover, we will dissect the multifaceted roles of TILs in tumour-specific immunity and melanoma immune escape. The significance of TILs in melanoma prognosis and cancer immunotherapy will also be discussed, with a particular focus on their potential utility as biomarkers of patient response. The goal of personalised medicine appears to be in realistic sight, as new immunomodulatory techniques and technological innovations continue to advance the field of cancer immunotherapy. In light of recent studies highlighting the possible utility of TILs in determining therapeutic outcome, further characterisation of TIL phenotype and function has the potential to help translate individualised care into current medical practice.